Management Team

PAUL E. FREIMAN

Chairman of the Board of Directors

Mr. Freiman joined NovaBay’s Board in 2002 and has held various positions during his 17 year tenure at the Company, including Lead Independent Director, Chairman of the Compensation Committee, and since March 2019, Chairman of the Board. Paul E. Freiman currently serves as Chairman of Penwest Pharmaceutical Co., and serves on the boards of Calypte Biomedical Corporation, NeoPharm, Inc., Otsuka America Pharmaceuticals, Inc., and SciGen Ltd. Mr. Freiman was most recently the President and CEO of Neurobiological Technologies Inc. Prior to this role, he held the position of Chairman and CEO of Syntex Corporation, which was sold to The Roche Group for $5.3 billion during his tenure.

Mr. Freiman holds a B.S. degree in pharmacy from Fordham University and an honorary doctorate from the Arnold & Marie Schwartz College of Pharmacy.

JUSTIN HALL, ESQ

Chief Executive Officer

Justin Hall joined NovaBay in February 2013 and currently serves as Company’s Chief Executive Officer & General Counsel. As the chief executive officer and chief legal counsel, Mr. Hall oversees all company operations, including sales, manufacturing, and business development. Prior to joining NovaBay, Mr. Hall worked as the Corporate Counsel of Accuray Incorporated, a radiation oncology company, which he joined in October 2006, where provided substantive legal advice on a broad range of complex legal matters. Mr. Hall’s prior experience also includes serving as a FINRA licensed investment advisor at Sagemark Consulting from 2000 to 2006, and a stock broker at First Security Van Kasper from 1998 to 2001.

Mr. Hall received a B.A. in Business Administration and Management from the University of California, San Diego, and a J.D. from the University of San Diego School of Law.

ANDREW JONES

Chief Financial Officer

Andrew Jones joined NovaBay in May 2020 and currently serves as the Company’s Chief Financial Officer. Prior to joining NovaBay, Mr. Jones most recently served as Vice President, Finance of MyoScience, Inc., a commercial-stage medical device company, through its acquisition by Pacira BioSciences. In this position, he was responsible for overseeing all accounting and finance functions as well as executive management and board-level reporting, including strategic planning decisions that resulted in significant revenue growth and gross margin improvements. Prior to MyoScience, Mr. Jones was Senior Director of Finance at Armetheon, Inc., a late-stage drug development company, and Corporate Controller of Asante Solutions, Inc., a medical device company now known as Bigfoot Biomedical, Inc., and Genelabs Technologies, Inc., a public biotechnology company acquired by GlaxoSmithKline. Earlier in his career he was a Senior Manager at PricewaterhouseCoopers providing clients with M&A advisory and audit services.

Mr. Jones holds a BA in business administration from the University of Washington.